EligibleTrials

Macrophage Imaging Using Ga-MMR-VHH2 in Lung Cancer Patients

Recruiting · NCT05933239 · Interventional (participants receive a specific treatment)

View the official record on ClinicalTrials.gov →
Lung cancer

Interventions studied

68GaNOTA-Anti-MMR-VHH2

What this trial is about

Phase II study to evaluate the clinical potential of 68GaNOTA-anti-MMR-VHH2 for in vivo imaging of Macrophage Mannose Receptor (MMR)-expressing Macrophages by means of Positron Emission Tomography (PET) in patients with non-small cell lung cancer (NSCLC) planned for surgical resection.

Who can take part

Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

1 location listed.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.